Biomedela - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 161,665 | 419,114 | 516,276 | 751,951 | 1,335,319 | 1,551,748 | 2,492,573 | 2,747,481 |
| Profit before tax | -31,920 | 1,692 | 14,753 | 33,872 | 117,791 | 39,520 | 295,492 | 367,283 |
| Net profit | -25,661 | 1,422 | 12,469 | 28,732 | 99,099 | 33,332 | 251,161 | 308,933 |
| Equity | -21,562 | -20,140 | -7,671 | 21,061 | 120,160 | 153,492 | 84,653 | 193,586 |
| Liabilities | 88,151 | 107,516 | 91,727 | 172,291 | 183,704 | 234,790 | 307,046 | 367,025 |
| Non-current assets | 8,250 | 9,112 | 8,091 | 3,464 | 4,380 | 3,763 | 5,990 | 7,171 |
| Current assets | 58,339 | 78,264 | 75,965 | 189,888 | 299,484 | 384,519 | 385,709 | 553,440 |
| Total assets | 66,589 | 87,376 | 84,056 | 193,352 | 303,864 | 388,282 | 391,699 | 560,611 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 124,892 | 62,662 | 56,432 |
| Social insurance contributions | - | - | - | - | - | 26,365 | 31,988 | 30,299 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +83.5% | +159.2% | +23.2% | +45.6% | +77.6% | +16.2% | +60.6% | +10.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -38.5% | 1.6% | 14.8% | 14.9% | 32.6% | 8.6% | 64.1% | 55.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 136.4% | 82.5% | 21.7% | 296.7% | 159.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -15.9% | 0.3% | 2.4% | 3.8% | 7.4% | 2.1% | 10.1% | 11.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -19.7% | 0.4% | 2.9% | 4.5% | 8.8% | 2.5% | 11.9% | 13.4% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 8.2 | 1.5 | 1.5 | 3.6 | 1.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 27,714 | 83,823 | 101,563 | 187,988 | 333,830 | 332,515 | 393,566 | 392,497 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biomedela - Social security debts
The company had no debts to Sodra
Biomedela - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biomedela, UAB is a Private Limited Liability Company active in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of €2.75M, up 10.2% year on year and 77.1% higher than two years earlier. Net profit reached €308.9K, compared with €251.2K in 2024 and €33.3K in 2023, showing a clear upward profitability trend. The 2025 net profit margin improved to 11.2% from 10.1% in 2024 and 2.1% in 2023, indicating stronger operating efficiency over the period. Balance sheet size also expanded, with total assets rising to €560.6K in 2025 from €391.7K in 2024, while equity increased to €193.6K and liabilities to €367.0K. The equity ratio stood at 34.5%, and debt-to-equity was 1.90, reflecting a leveraged but still solid capital structure. Asset turnover remained high at 4.90x, and revenue per employee was €392.5K, supporting a picture of efficient asset and staff use.